Letters to the Editor
Vol. 1 No. 2 (2022)
https://doi.org/10.4081/btvb.2022.28

Treatment of venous thromboembolism in pregnancy: findings from the RIETE Registry

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Venous thromboembolism, Pregnancy, Low-molecular- weight heparin, Anticoagulation
Received: 21 March 2022
Accepted: 6 May 2022
Published: 23 May 2022
5239
Views
594
Downloads

Authors

Paolo Prandoni
prandonip@gmail.com
Arianna Foundation on Anticoagulation, Bologna, Italy.
Franca Bilora
Department of Medicine, University Hospital of Padua, Italy.
Raffaele Pesavento
Division of Medicine, Civic Hospital of Montebelluna, Italy.
Giorgina Salgueiro
Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain.
Angeles Blanco-Molina
Department of Internal Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain.
Raquel Lòpez-Reyes
Department of Internal Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain.
Manuel Monreal
Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
and the RIETE Investigators

Venous thromboembolism (VTE) is one of the leading cardiovascular etiologies of maternal morbidity and mortality. Indeed, pulmonary embolism (PE) accounts for approximately 9% of pregnancy-related deaths. In addition, pregnancy-related deep-vein thrombosis (DVT) can lead to (severe) post-thrombotic syndrome [...]

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Bukhari S, Fatima S, Barakat AF, et al. Venous thromboembolism during pregnancy and postpartum period. Eur J Intern Med 2022;97:8-17. DOI: https://doi.org/10.1016/j.ejim.2021.12.013
Abe K, Kuklina EV, Hooper WC, Callaghan WM. Venous thromboembolism as a cause of severe maternal morbidity and mortality in the United States. Semin Perinatol 2019;43:200-4. DOI: https://doi.org/10.1053/j.semperi.2019.03.004
Wik HS, Jacobsen AF, Sandvik L, Sandset PM. Prevalence and predictors for postthrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. J Thromb Haemost 2012;10:840-7. DOI: https://doi.org/10.1111/j.1538-7836.2012.04690.x
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020:41:543-603.
Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021;61:9-82. DOI: https://doi.org/10.1016/j.ejvs.2020.09.023
Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018;2:3317-59. DOI: https://doi.org/10.1182/bloodadvances.2018024802
Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8. DOI: https://doi.org/10.1182/blood-2002-01-0108
Lee A, Levine MN, Baker RI, et al. Investigators Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53. DOI: https://doi.org/10.1056/NEJMoa025313
Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-24. DOI: https://doi.org/10.1056/NEJMoa1711948
Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607. DOI: https://doi.org/10.1056/NEJMoa1915103
Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemostas 1994;72:191-7. DOI: https://doi.org/10.1055/s-0038-1648837
Gonzales-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999;30:283-92. DOI: https://doi.org/10.1016/S0741-5214(99)70139-4
Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26-31. DOI: https://doi.org/10.1055/s-0037-1614412
Simard C, Malhamé I, Skeith L, Carson MP, Rey E, Tagalakis V; Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network. Management of anticoagulation in pregnant women with venous thromboembolism: An international survey of clinical practice. Thromb Res 2022;210:20-5. DOI: https://doi.org/10.1016/j.thromres.2021.12.016
Bikdeli B, Jiménez D, Hawkins M, et al. Rationale, design and methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thromb Haemost 2018;118:214-24. DOI: https://doi.org/10.1160/TH17-07-0511

How to Cite



1.
Prandoni P, Bilora F, Pesavento R, Salgueiro G, Blanco-Molina A, Lòpez-Reyes R, et al. Treatment of venous thromboembolism in pregnancy: findings from the RIETE Registry. Bleeding Thromb Vascul Biol [Internet]. 2022 May 23 [cited 2025 Sep. 6];1(2). Available from: https://www.btvb.org/btvb/article/view/28
Copyright (c) 2022 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.